This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months

This study has been completed.
Information provided by:
Changi General Hospital Identifier:
First received: July 8, 2008
Last updated: June 15, 2011
Last verified: June 2011
The purpose of this study is to explore the changes in metabolic parameters in patients treated with escitalopram for six months for major depression, generalized anxiety disorder or panic disorder, with or without agoraphobia.

Major Depression Generalized Anxiety Disorder Panic Disorder

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Open-label Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months

Resource links provided by NLM:

Further study details as provided by Changi General Hospital:

Enrollment: 27
Study Start Date: September 2008
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Detailed Description:

This is an open-label study, with 4 scheduled visits. Recruitment of 100 subjects. Assessments include demographics, diagnosis, smoking frequency, Clinical Global Scale (CGI-S), weight, height,blood pressure, waist and hip circumference and fasting blood glucose and lipd profile.

Statistical analysis will be exploratory and mainly descriptive.


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Outpatients in psychiatric clinic in a general hosptial

Inclusion Criteria:

  • Give informed consent
  • Requires pharmacological treatment with escitalopram for major depression, generalized anxiety disorder or panic disorder
  • Aged 21 years old and above
  • Able to comprehend and comply with protocol
  • Not pregnant and if of child-bearing age, using adequate methods of contraception

Exclusion Criteria:

  • Currently taking or has taken in previous 3 months, any other antidepressants, antipsychotics, mood stabilizers, weight loss or lipid-profile modifying drugs
  • Contraindications to escitalopram
  • Unstable medical illness and/or is already under treatment of diabetes, hypertension, dyslipidemia, ischemic heart disease
  • History of non-response to escitalopram
  • Meets IDF definition of metabolic syndrome
  • Significant risk of suicide
  • Primary diagnosis or comorbid diagnosis of psychotic disorder, bipolar disorder, substance dependence and/or dementia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00711737

Changi General Hospital
Singapore, Singapore, 529889
Sponsors and Collaborators
Changi General Hospital
Principal Investigator: Lai H Peh, MBBS Changi General Hospital
  More Information

Responsible Party: Changi General Hospital Identifier: NCT00711737     History of Changes
Other Study ID Numbers: 2008.06
Study First Received: July 8, 2008
Last Updated: June 15, 2011

Keywords provided by Changi General Hospital:
metabolic parameters
metabolic syndrome

Additional relevant MeSH terms:
Anxiety Disorders
Depressive Disorder, Major
Panic Disorder
Pathologic Processes
Mental Disorders
Depressive Disorder
Mood Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents processed this record on September 21, 2017